Important Safety Information

Renovia encourages you to promptly report any side effect or adverse reaction to your licensed healthcare provider and to the pharmacy that dispensed your medication. You may also report suspected reactions to the FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.

If you are experiencing a medical emergency, call 911 or go to your nearest emergency department.

This page is not comprehensive and does not replace the labeling that accompanies your medication or the guidance of your clinician. Discuss any questions or concerns with your healthcare provider.

All advertisements on joinrenovia.com are paid for by Renovia Health, Inc. and are intended to market Renovia's services. Some advertisements may feature paid actors or dramatizations. When real Renovia patients are shown, they may have been compensated for their time. Individual results vary and are not guaranteed.

Compounded drugs are not FDA-approved and do not undergo clinical studies evaluating safety and efficacy in the way commercially available, FDA-approved products do. Compounded products may still be legally prescribed, and a licensed clinician may issue a prescription for a compounded product based on your medical consultation.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, along with a reduced-calorie diet and increased physical activity, for people with an initial body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia.

Boxed warning — possible thyroid tumors, including cancer. In studies with rodents, semaglutide caused thyroid tumors, including thyroid cancer. It is not known whether semaglutide causes medullary thyroid carcinoma (MTC) in humans. Tell your provider if you develop a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.

Do not use semaglutide if:

• You or a family member has ever had medullary thyroid carcinoma (MTC).
• You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• You have had a serious allergic reaction to semaglutide.

Tell your provider before starting if you:

• Have or have had problems with your pancreas or kidneys.
• Have type 2 diabetes with a history of diabetic retinopathy.
• Have or have had depression, suicidal thoughts, or other mental health conditions.
• Are pregnant or plan to become pregnant. Semaglutide should not be used during pregnancy; stop using it at least 2 months before a planned pregnancy.
• Are breastfeeding or plan to breastfeed.

Tell your provider about all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Serious side effects may include:

• Thyroid C-cell tumors (see boxed warning above).
• Inflammation of the pancreas (pancreatitis) — stop use and contact your provider for severe, persistent abdominal pain, with or without vomiting.
• Paralysis of the stomach (gastroparesis) — early fullness, prolonged fullness, nausea, vomiting.
• Gallbladder problems, including gallstones, which may require surgery.
• Low blood sugar (hypoglycemia), especially in people with type 2 diabetes.
• Kidney problems, including kidney failure, often related to dehydration from vomiting or diarrhea.
• Serious allergic reactions — swelling of the face, lips, tongue, or throat; trouble breathing or swallowing; severe rash; fainting.
• Changes in vision in people with type 2 diabetes.
• Increased resting heart rate.
• Depression or thoughts of suicide — report any new or worsening mood or behavior changes immediately.

Most common side effects: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, upset stomach, dizziness, bloating, belching, gas, stomach flu, heartburn, and runny nose or sore throat.

Administration. Semaglutide may be taken with or without food. It is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once weekly on the same day each week. Do not change your dose or stop treatment without first discussing it with your clinician.

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and GLP-1 receptor agonist used for chronic weight management, along with a reduced-calorie diet and increased physical activity, for people with an initial BMI of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

Boxed warning — possible thyroid tumors, including cancer. In studies with rodents, tirzepatide caused thyroid tumors, including thyroid cancer. It is not known whether tirzepatide causes MTC in humans. Report any lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath to your provider.

Do not use tirzepatide if:

• You or a family member has ever had medullary thyroid carcinoma (MTC).
• You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• You have had a serious allergic reaction to tirzepatide.

Serious side effects may include: pancreatitis, gallbladder problems, hypoglycemia (particularly with insulin or insulin secretagogues), acute kidney injury from dehydration, serious allergic reactions, diabetic retinopathy complications, severe gastrointestinal disease, and depression or thoughts of suicide.

Most common side effects: nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, hypersensitivity reactions, belching, hair loss, and heartburn.

Effect on oral medications. Tirzepatide delays gastric emptying and may reduce the effectiveness of oral hormonal contraceptives. Discuss a non-oral contraceptive method or a backup method with your clinician.

Administration. Tirzepatide is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once weekly on the same day each week, with or without food. Do not change your dose or stop treatment without speaking to your clinician.

GLP-1 medications are not recommended during pregnancy or breastfeeding. If you are pregnant, planning to become pregnant, or breastfeeding, tell your clinician before starting treatment. Weight loss and delayed gastric emptying may affect the absorption of oral contraceptives; discuss contraception with your clinician.

Report side effects to your clinician and the dispensing pharmacy. You may also report to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For non-urgent questions, email taciano@renovia.health.